<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860844</url>
  </required_header>
  <id_info>
    <org_study_id>ACT15378</org_study_id>
    <secondary_id>PIP - 2018‐002697‐45</secondary_id>
    <secondary_id>U1111-1202-1096</secondary_id>
    <nct_id>NCT03860844</nct_id>
  </id_info>
  <brief_title>Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia</brief_title>
  <acronym>ISAKIDS</acronym>
  <official_title>Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the anti-leukemic activity of isatuximab in combination with standard
      chemotherapies in pediatric participants of ages 28 days to less than 18 years with
      Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML)

      Secondary Objectives:

        -  Safety and tolerability assessments

        -  Assessment of infusion reactions (IRs)

        -  Pharmacokinetics (PK) of isatuximab

        -  Minimal residual disease

        -  Overall response rate

        -  Overall survival

        -  Event free survival

        -  Duration of response

        -  Relationship between clinical effects and CD38 receptor density and occupancy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include a screening period of up to 21 days (Day -21 to -1), a study treatment
      period [Day 1 to Day 57 for Acute Lymphoblastic Leukemia (ALL); Day 1 to Day 22 for Acute
      Myeloid Leukemia (AML)], a recovery period (until an end of treatment visit [within 30 days
      after hematological recovery]) and a follow-up period (until final analysis cut off date).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) rate in acute myeloid leukemia (AML) cohort</measure>
    <time_frame>Baseline to Day 22</time_frame>
    <description>Morphological CR rate defined as the proportion of participants with CR or CRi (CR with incomplete peripheral recovery)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) rate in B-cell acute lymphoblastic leukemia (B-ALL) cohort</measure>
    <time_frame>Baseline to Day 57</time_frame>
    <description>Morphological CR rate defined as the proportion of participants with CR or CRi</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) rate in T-cell acute lymphoblastic leukemia (T-ALL) cohort</measure>
    <time_frame>Baseline to Day 57</time_frame>
    <description>Morphological CR rate defined as the proportion of participants with CR or CRi</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessments</measure>
    <time_frame>Baseline to approximately 3 months</time_frame>
    <description>Number of adverse events and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of infusion reactions</measure>
    <time_frame>Time from isatuximab infusion to resolution (approximately 2 days)</time_frame>
    <description>Incidence and severity of infusion reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of isatuximab: Cmax</measure>
    <time_frame>Day 1 to 30 days after hematological recovery</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of isatuximab: Ctrough</measure>
    <time_frame>Day 1 to 30 days after hematological recovery</time_frame>
    <description>Concentration observed just before treatment administration during repeated dosing (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of isatuximab: AUC</measure>
    <time_frame>Day 1 to 30 days after hematological recovery</time_frame>
    <description>Partial area under the serum concentration time curve: AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease</measure>
    <time_frame>On day 43</time_frame>
    <description>Estimation of minimal residual disease in participants achieving CR or CRi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>On day 43</time_frame>
    <description>The overall response rate is defined as the proportion of participants with CR or CRi for blood and bone marrow disease; Partial response (PR) based on the National Comprehensive Cancer Network (NCCN) guideline will be considered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline to approximately 3 months</time_frame>
    <description>Overall survival is defined as the time interval from the date of first study treatment administration to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>Baseline to approximately 3 months</time_frame>
    <description>Event free survival is defined as the time interval from the date of first study treatment administration to the date of the first of: completion or going off protocol induction/consolidation therapy without CR, relapse from CR, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Time from the first response to the first disease progression or death</time_frame>
    <description>Duration of response is defined as the time from the date of the first response to the date of first disease progression or death from any cause, whichever happens first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD38 receptor density and occupancy</measure>
    <time_frame>Baseline to Day 15</time_frame>
    <description>CD38 receptor density and occupancy will be assessed at baseline and at Day 15 and correlated with clinical endpoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute Myeloid Leukemia (AML) cohort: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
    <other_name>SAR650984</other_name>
    <other_name>Sarclisa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal daunorubicin</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>AML cohort or ALL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG Asparaginase</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Intravenous</description>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL) cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participant must be 28 days to less than 18 years of age, at the time of signing the
             informed consent.

          -  Participants must have a confirmed diagnosis of relapsed Acute Lymphoblastic Leukemia
             (ALL) of T- or B-cell origin including T-lymphoblastic lymphoma (LBL), or relapsed
             Acute Myeloblastic Leukemia (AML) including participants with history of
             myelodysplasia.

          -  Participants must be previously treated for their disease and have relapsed or are
             refractory to most recent treatment. Participants in first or second relapse will be
             eligible regardless of the remission duration.

          -  Participants with no more than 1 prior salvage therapy.

        Exclusion criteria:

          -  Any serious active disease or co-morbid condition which, in the opinion of the
             Investigator, may interfere with the safety of the study treatment or the compliance
             with the study protocol.

          -  Participants must have been off prior treatment with immunotherapy/investigational
             agents and chemotherapy for &gt;2 weeks and must have recovered from acute toxicity
             before the first study treatment administration. Treatment may start earlier if
             necessitated by the patient's medical condition (eg, rapidly progressive disease)
             following discussion with the Sponsor.

          -  Prior stem cell transplant within 3 months and/or evidence of active systemic Graft
             versus Host Disease (GVHD) and/or immunosuppressive therapy for GVHD within 1 week
             before the first study treatment administration.

          -  Participants with LBL with bone marrow blasts &lt;5%.

          -  Participants with Burkitt-type ALL.

          -  Acute leukemia with testicular or central nerve system involvement alone.

          -  Participants who have developed therapy related acute leukemia.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 0320001</name>
      <address>
        <city>Córdoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560001</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760007</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035 003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240003</name>
      <address>
        <city>Montreal</city>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Vancouver</city>
        <zip>V6H3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2080001</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2460001</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500005</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Paris Cedex 19</city>
        <zip>75935</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800002</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100001</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100003</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100002</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280001</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5780001</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5780002</name>
      <address>
        <city>Oslo</city>
        <zip>0342</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7520001</name>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-CD38 monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

